{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:07:35Z","timestamp":1791936455054,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-16-12102"],"award-info":[{"award-number":["ESR-16-12102"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Lady Garden Foundation"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1136\/ijgc-2021-002973","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T11:30:55Z","timestamp":1631532655000},"page":"1471-1475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct0405269","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03425565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03682289","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03842228","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03297424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03682289","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04065269","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Susana","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Toms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Khalique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoma","family":"Attygalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Vroobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Natrajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002973_bb0010","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2021-002973_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","article-title":"Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study","volume":"18","author":"Takano","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002973_bb0020","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ygyno.2020.09.048","article-title":"A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer","volume":"159","author":"Hall","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002973_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2021-002973_bb0030","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002973_bb0035","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","article-title":"Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes","volume":"175","author":"Mashtalir","year":"2018","journal-title":"Cell"},{"key":"10.1136\/ijgc-2021-002973_bb0040","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The p270 (ARID1A\/SMARCF1) subunit of mammalian Swi\/Snf-related complexes is essential for normal cell cycle arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-002973_bb0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2021-002973_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"10.1136\/ijgc-2021-002973_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2021-002973_bb0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature12146","article-title":"BAF complexes facilitate decatenation of DNA by topoisomerase II\u03b1","volume":"497","author":"Dykhuizen","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2021-002973_bb0065","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-002973_bb0070","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.dnarep.2006.12.015","article-title":"ATR signaling mediates an S-phase checkpoint after inhibition of poly(ADP-ribose) polymerase activity","volume":"6","author":"Horton","year":"2007","journal-title":"DNA Repair"},{"key":"10.1136\/ijgc-2021-002973_bb0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev"},{"key":"10.1136\/ijgc-2021-002973_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cjp2.103","article-title":"Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers","volume":"4","author":"Khalique","year":"2018","journal-title":"J Pathol Clin Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24021406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24021406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:48Z","timestamp":1753234008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24021406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1048891X24021406"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002973","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https:\/\/creativecommons.org\/licenses\/by\/4.0\/.","name":"copyright","label":"Copyright"}]}}